Origin Home Health Care | |
441 Apollo Beach Blvd, Apollo Beach, Florida 33572 | |
(813) 672-3949 | |
Name | Origin Home Health Care |
---|---|
Location | 441 Apollo Beach Blvd, Apollo Beach, Florida |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Home Health Aide |
Medicare ID | 109060 |
Ownership Type | Proprietary |
Service Area Zip Codes | 33510, 33511, 33527, 33534, 33547, 33549, 33559, 33563, 33565, 33566, 33567, 33569, 33570, 33572, 33573, 33578, 33579, 33584, 33592, 33594, 33596, 33598, 33602, 33603, 33604, 33605, 33607, 33609, 33610, 33611, 33612, 33613, 33614, 33615, 33616, 33617, 33618, 33619, 33624, 33625, 33626, 33629, 33634, 33635, 33637, 33805, 33843, 33844, 33850, 33860, 33868, 33898 |
NPI Number | 1437335627 |
Organization Name | GENESIS HEALTHCARE, LLC |
Doing Business As | ORIGIN HOME HEALTH CARE |
Address | 441 Apollo Beach Blvd, Apollo Beach, FL 33572 |
Phone Number | 813-672-3949 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases, has received a grant in the amount of $150,000 from the National Science Foundation to support the development of antimicrobial sutures. PolyMedix has developed a series of novel antimicrobial polymers for device and material applications, which it collectively calls the PolyCides™.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
In a post in the Global Health Technologies Coalition's "Breakthroughs" blog, GHTC's Kim Lufkin reports on her travels to Kenya this month "to visit global health research projects and see the impact on people in the country," writing, "Although we visited a range of projects, I was left with the lasting impression that much of this research is so close to producing new health tools that can lead to amazing innovations in public health," including "the first ever malaria vaccine, gels women can use to protect themselves from HIV, and new drugs for neglected diseases that affect the poorest of the poor."
The lesson learned in eradicating dandelions from your yard could apply in treating breast cancer as well, said researchers from Baylor College of Medicine in Houston in a report that appears online today in the Journal of the National Cancer Institute.
› Verified 8 days ago
Quality Rating: |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases, has received a grant in the amount of $150,000 from the National Science Foundation to support the development of antimicrobial sutures. PolyMedix has developed a series of novel antimicrobial polymers for device and material applications, which it collectively calls the PolyCides™.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
In a post in the Global Health Technologies Coalition's "Breakthroughs" blog, GHTC's Kim Lufkin reports on her travels to Kenya this month "to visit global health research projects and see the impact on people in the country," writing, "Although we visited a range of projects, I was left with the lasting impression that much of this research is so close to producing new health tools that can lead to amazing innovations in public health," including "the first ever malaria vaccine, gels women can use to protect themselves from HIV, and new drugs for neglected diseases that affect the poorest of the poor."
The lesson learned in eradicating dandelions from your yard could apply in treating breast cancer as well, said researchers from Baylor College of Medicine in Houston in a report that appears online today in the Journal of the National Cancer Institute.
› Verified 8 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 81.3 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 97.8 | 98.6 |
How often the home health team checked patients’ risk of falling | 100 | 99.6 |
How often the home health team checked patients for depression | 98.7 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 52.4 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 49 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 99.2 | 96.4 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases, has received a grant in the amount of $150,000 from the National Science Foundation to support the development of antimicrobial sutures. PolyMedix has developed a series of novel antimicrobial polymers for device and material applications, which it collectively calls the PolyCides™.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
In a post in the Global Health Technologies Coalition's "Breakthroughs" blog, GHTC's Kim Lufkin reports on her travels to Kenya this month "to visit global health research projects and see the impact on people in the country," writing, "Although we visited a range of projects, I was left with the lasting impression that much of this research is so close to producing new health tools that can lead to amazing innovations in public health," including "the first ever malaria vaccine, gels women can use to protect themselves from HIV, and new drugs for neglected diseases that affect the poorest of the poor."
The lesson learned in eradicating dandelions from your yard could apply in treating breast cancer as well, said researchers from Baylor College of Medicine in Houston in a report that appears online today in the Journal of the National Cancer Institute.
› Verified 8 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 72.9 | 79.6 |
How often patients got better at getting in and out of bed | 65.4 | 81.1 |
How often patients got better at bathing | 75.4 | 82.3 |
How often patients’ breathing improved | 63.8 | 82.8 |
How often patients’ wounds improved or healed after an operation | 89.4 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 65 | 75 |
How often home health patients had to be admitted to the hospital | 9.1 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 5.3 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 98.5 | 94 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases, has received a grant in the amount of $150,000 from the National Science Foundation to support the development of antimicrobial sutures. PolyMedix has developed a series of novel antimicrobial polymers for device and material applications, which it collectively calls the PolyCides™.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
In a post in the Global Health Technologies Coalition's "Breakthroughs" blog, GHTC's Kim Lufkin reports on her travels to Kenya this month "to visit global health research projects and see the impact on people in the country," writing, "Although we visited a range of projects, I was left with the lasting impression that much of this research is so close to producing new health tools that can lead to amazing innovations in public health," including "the first ever malaria vaccine, gels women can use to protect themselves from HIV, and new drugs for neglected diseases that affect the poorest of the poor."
The lesson learned in eradicating dandelions from your yard could apply in treating breast cancer as well, said researchers from Baylor College of Medicine in Houston in a report that appears online today in the Journal of the National Cancer Institute.
› Verified 8 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | Not Available |
Health team communicated well with them | Not Available |
Health team discussed medicines, pain, and home safety | Not Available |
How patients rated overall care from agency | Not Available |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases, has received a grant in the amount of $150,000 from the National Science Foundation to support the development of antimicrobial sutures. PolyMedix has developed a series of novel antimicrobial polymers for device and material applications, which it collectively calls the PolyCides™.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
In a post in the Global Health Technologies Coalition's "Breakthroughs" blog, GHTC's Kim Lufkin reports on her travels to Kenya this month "to visit global health research projects and see the impact on people in the country," writing, "Although we visited a range of projects, I was left with the lasting impression that much of this research is so close to producing new health tools that can lead to amazing innovations in public health," including "the first ever malaria vaccine, gels women can use to protect themselves from HIV, and new drugs for neglected diseases that affect the poorest of the poor."
The lesson learned in eradicating dandelions from your yard could apply in treating breast cancer as well, said researchers from Baylor College of Medicine in Houston in a report that appears online today in the Journal of the National Cancer Institute.
› Verified 8 days ago
The patient survey data of Origin Home Health Care is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 85 | 88 |
Percent of patients who reported that their home health team communicated well with them | 82 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 76 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 90 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 61 | 78 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases, has received a grant in the amount of $150,000 from the National Science Foundation to support the development of antimicrobial sutures. PolyMedix has developed a series of novel antimicrobial polymers for device and material applications, which it collectively calls the PolyCides™.
Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.
In a post in the Global Health Technologies Coalition's "Breakthroughs" blog, GHTC's Kim Lufkin reports on her travels to Kenya this month "to visit global health research projects and see the impact on people in the country," writing, "Although we visited a range of projects, I was left with the lasting impression that much of this research is so close to producing new health tools that can lead to amazing innovations in public health," including "the first ever malaria vaccine, gels women can use to protect themselves from HIV, and new drugs for neglected diseases that affect the poorest of the poor."
The lesson learned in eradicating dandelions from your yard could apply in treating breast cancer as well, said researchers from Baylor College of Medicine in Houston in a report that appears online today in the Journal of the National Cancer Institute.
› Verified 8 days ago
Origin Home Health Care Location: 441 Apollo Beach Blvd, Apollo Beach, Florida 33572 Ratings: Phone: (813) 672-3949 |